Evidence map›Paper›PMID 36091127›Full record

ArticleFrontiers in oncology2022

Cervical cancer screening in high-altitude areas in China: A large cross-section study of 25,173 women in northern Tibet.

Qimin Wang, Yingying He, Fang Long, Chaoran Li, Zhuowei Shen, Dongxing Guo, Duoji Zhaxi, Lamu Bumu, Zhengyu Hua, Zhigang Sun and 8 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Qimin WangInstitute of High Altitude Medicine, People's Hospital of Nagqu affiliated to Dalian Medical University, Nagqu, China.
Yingying HeInstitute of High Altitude Medicine, People's Hospital of Nagqu affiliated to Dalian Medical University, Nagqu, China.
Fang LongInstitute of High Altitude Medicine, People's Hospital of Nagqu affiliated to Dalian Medical University, Nagqu, China.
Chaoran LiDepartment of Obstetrics and Gynecology, First Affiliated Hospital of Dalian Medical University, Dalian, China.
Zhuowei ShenInstitute of High Altitude Medicine, People's Hospital of Nagqu affiliated to Dalian Medical University, Nagqu, China.
Dongxing GuoInstitute of High Altitude Medicine, People's Hospital of Nagqu affiliated to Dalian Medical University, Nagqu, China.
Duoji ZhaxiInstitute of High Altitude Medicine, People's Hospital of Nagqu affiliated to Dalian Medical University, Nagqu, China.
Lamu BumuDepartment of Obstetrics and Gynecology, People's Hospital of Nagqu affiliated to Dalian Medical University, Nagqu, China.
Zhengyu HuaDepartment of Pathology, First Affiliated Hospital of Dalian Medical University, Dalian, China.
Zhigang SunDepartment of Pathology, First Affiliated Hospital of Dalian Medical University, Dalian, China.
Nan JiangDepartment of Pathology, First Affiliated Hospital of Dalian Medical University, Dalian, China.
Xu HanDepartment of Obstetrics and Gynecology, First Affiliated Hospital of Dalian Medical University, Dalian, China.
Jing LiDepartment of Obstetrics and Gynecology, First Affiliated Hospital of Dalian Medical University, Dalian, China.
Keqing YanDepartment of Pathology, Second Affiliated Hospital of Dalian Medical University, Dalian, China.
Siqi BaiDepartment of Obstetrics and Gynecology, First Affiliated Hospital of Dalian Medical University, Dalian, China.
Muhan TaoDepartment of Obstetrics and Gynecology, First Affiliated Hospital of Dalian Medical University, Dalian, China.
Xiaoguang XuInstitute of High Altitude Medicine, People's Hospital of Nagqu affiliated to Dalian Medical University, Nagqu, China.
Zhen XiaoInstitute of High Altitude Medicine, People's Hospital of Nagqu affiliated to Dalian Medical University, Nagqu, China.
Dalian Medical University · CNFirst Affiliated Hospital of Dalian Medical University · CNDalian Maternal and Child Health Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cervical cancer has become a worldwide concern owing to its high incidence and mortality rates. To date, high-altitude areas of Tibet have not benefited from any large-scale cervical cancer screening programs. Therefore, we initiated a screening program to investigate the prevalence of human papilloma virus (HPV) and HPV genotype distribution to reveal cervical cancer and its precursor which lead to morbidity among women in the city of Nagqu in northern Tib3et. Methods: A total of 25,173 women were recruited to undergo HPV genotype tests between June and December 2019. Women infected with HPV 16 and/or 18 underwent colposcopy and histological examination. Women with other high-risk HPV type (hr-HPV) underwent cytological tests to determine whether to conduct further colposcopy and histological examination for diagnosis. HPV prevalence was calculated in the total population and further stratified according to various parameters, such as age group, area location (altitude level), and single or mixed infection status. The HPV genotype distribution was also investigated accordingly. Cervical lesions revealed by further colposcopic findings were also analyzed; high-grade and malignant lesion morbidities were calculated in total and in each county. Most data were collected and analyzed using descriptive and consistency check statistical methods, and a risk factor investigation for HPV infection was performed using logistic regression models. Results: The total HPV infection rate among women in Nagqu was 13.42%. Of the 25,173 women in the study, 999 (3.97%) were HPV 16/18 positive, 2,379 (9.45%) were other hr-HPV-positive, and 21,795 (86.58%) were HPV-negative. The five most common HPV genotypes, accounting for more than 60% of all HPV infections in Nagqu people, were HPV 16, 58, 31, 18, and 52. Tibetan women younger than 20 years and older than 60 years were the two age groups with the highest rates of HPV infection, 26.7% and 19.8%, respectively. Among the HPV-positive women, 2,656 (78.33%) were infected with a single strain and 732 (21.67%) were infected with multiple strains (more than two genotypes). HPV prevalence increased in high-altitude areas (positive rate highest in Nyima with an altitude of 5,000 m, 23.9%) and decreased in relatively low-altitude areas (positive rate lowest in Lhari with an altitude of 4,000 m, 6.6%). Multiple analyses showed that age, parity, age at first delivery, and altitude of residence were independent factors facilitating HPV infection in Tibetan women. High-grade and malignant cervical lesions revealed by histological findings were different among living locations, with the highest rates in Xainza, Baingoin, and Nyainrong, these being 2.019%, 1.820%, and 1.116%, respectively, among women in these areas. Conclusion: Our survey provides an overall perspective on HPV genotype infection and cervical lesions in women in northern Tibet. The data not only provide useful information for the treatment of cervical lesions but also has great value in terms of the primary and secondary prevention measures that can be taken for women living in these regions. Clinical Trial Registration: www.chictr.org.cn, indentifier ChiCTR2000035061.

Indexed as

cervical cancercervical cancer screeningdisease distributiongenotypeHPV

Identifiers

PMID36091127
PMCPMC9452642
OpenAlexW4293221227

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.